Search Results

Daxor Corporation, the global leader in blood volume measurement technology, announces new data from Duke University Medical Center validating the benefits of blood volume analysis in optimizing individualized therapy for heart failure patients with impaired renal function.

QT Imaging Holdings, Inc. is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.

The University of Cincinnati Cancer Center inaugurated its state-of-the-art Blood Cancer Healing Center, revolutionizing blood cancer care in the United States.

BostonGene today announced a master agreement with Duke University School of Medicine to collaborate on multiple research projects across lung cancer, gastrointestinal, genitourinary and skin cancers.

With Alzheimer’s disease expected to afflict 12.7 million Americans by 2050, researchers at Penn State University and Duke University Medical Center are advancing our understanding of the disease’s behavior in different people – making personalized, optimized treatment possible for the first time. And they’re doing it with math.

EvoEndo®, Inc. announces that Duke Health is the first provider in the region to bring Sedation-Free TNE of the Upper Gastrointestinal Tract using the EvoEndo® Single-Use Endoscopy System to patients in North Carolina.

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the University of Nebraska Medical Center (UNMC) is now enrolling patients with Locally Advanced Pancreatic Cancer (LAPC) in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial.

Curiox Biosystems is pleased to announce the establishment of the Curiox Innovation Center for the Curiox C-FREE™ Pluto LT System at the Human Immune Monitoring Center (HIMC) at Stanford University.

Lumos Pharma, Inc., a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer, effective January 1, 2024.